Interacciones de Candesartán

Candesartán (Atacand), antagonista de los receptores de la angiotensina II (ARA-II), tiene 184 interacciones documentadas en las etiquetas de la FDA y las hojas informativas que indexamos. Graves: 28; moderadas: 138; leves: 18; casos en los que una etiqueta indica que no hay ninguna interacción significativa: 0. Cada entrada de abajo cita la frase que la respalda. Esta página del medicamento es un punto de partida, no un veredicto sobre su situación.

Qué aspecto tiene Candesartán

Todas las versiones (20)
Candesartán, tableta de 4 mg: blanca, redonda, 7 mm, ranurada, con la inscripción ACF en una cara y 004 en la otra.
ACF / 004
4 mg · blanca · redonda · 7 mm · ranurada
ANI
Candesartán, tableta de 8 mg: rosa, redonda, 7 mm, ranurada, con la inscripción ACG en una cara y 008 en la otra.
ACG / 008
8 mg · rosa · redonda · 7 mm · ranurada
ANI
Candesartán, tableta de 16 mg: rosa, redonda, 7 mm, ranurada, con la inscripción ACH en una cara y 016 en la otra.
ACH / 016
16 mg · rosa · redonda · 7 mm · ranurada
ANI
Candesartán, tableta de 32 mg: rosa, redonda, 10 mm, ranurada, con la inscripción ACL en una cara y 032 en la otra.
ACL / 032
32 mg · rosa · redonda · 10 mm · ranurada
ANI

Representaciones generadas a partir de los listados de productos de las etiquetas de la FDA: color, forma, tamaño e inscripción. 20 versiones documentadas de 8 etiquetadores.

Interacciones según la etiqueta

Interacciones graves (28)

  • AliskirenoantihipertensivoGrave

    Do not co-administer aliskiren with candesartan cilexetil in patients with diabetes [see Drug Interactions (7.4) ] . (etiqueta de Candesartán, Contraindicaciones)

  • Amlodipino y benazeprilbloqueador de los canales de calcio dihidropiridínicoGrave

    Triple combination of candesartan cilexetil with an ACE-inhibitor and a mineralocorticoid receptor antagonist is generally not recommended. (etiqueta de Candesartán, Interacciones medicamentosas)

  • Benazeprilinhibidor de la ECAGrave

    Triple combination of candesartan cilexetil with an ACE-inhibitor and a mineralocorticoid receptor antagonist is generally not recommended. (etiqueta de Candesartán, Interacciones medicamentosas)

  • Benazepril e hidroclorotiazidainhibidor de la ECAGrave

    Triple combination of candesartan cilexetil with an ACE-inhibitor and a mineralocorticoid receptor antagonist is generally not recommended. (etiqueta de Candesartán, Interacciones medicamentosas)

  • Captoprilinhibidor de la ECAGrave

    Triple combination of candesartan cilexetil with an ACE-inhibitor and a mineralocorticoid receptor antagonist is generally not recommended. (etiqueta de Candesartán, Interacciones medicamentosas)

  • ClozapinaantipsicóticoGrave

    Use CLOZARIL cautiously in patients with cardiovascular or cerebrovascular disease or conditions predisposing to hypotension (e.g., dehydration, use of antihypertensive medications) [see Dosage and Administration ( 2.2 , 2.6 ), Warnings and Precautions ( 5.2 )]. (etiqueta de Clozapina, Advertencia en recuadro)

  • Enalaprilinhibidor de la ECAGrave

    Triple combination of candesartan cilexetil with an ACE-inhibitor and a mineralocorticoid receptor antagonist is generally not recommended. (etiqueta de Candesartán, Interacciones medicamentosas)

  • Enalapril e hidroclorotiazidainhibidor de la ECAGrave

    Triple combination of candesartan cilexetil with an ACE-inhibitor and a mineralocorticoid receptor antagonist is generally not recommended. (etiqueta de Candesartán, Interacciones medicamentosas)

  • Enalaprilatoinhibidor de la ECAGrave

    Triple combination of candesartan cilexetil with an ACE-inhibitor and a mineralocorticoid receptor antagonist is generally not recommended. (etiqueta de Candesartán, Interacciones medicamentosas)

  • Eplerenonaantagonista de la aldosteronaGrave

    Triple combination of candesartan cilexetil with an ACE-inhibitor and a mineralocorticoid receptor antagonist is generally not recommended. (etiqueta de Candesartán, Interacciones medicamentosas)

  • Eptifibatidaantiagregante plaquetarioGrave

    …of active abnormal bleeding within the previous 30 days Severe hypertension (systolic blood pressure >200 mm Hg or diastolic blood pressure >110 mm Hg) not adequately controlled on antihypertensive therapy Major surgery within the preceding 6 weeks History of stroke within 30 days or any history of hemorrhagic stroke Current or planned administration of another… (etiqueta de Eptifibatida, Contraindicaciones)

  • Espironolactonaantagonista de la aldosteronaGrave

    Triple combination of candesartan cilexetil with an ACE-inhibitor and a mineralocorticoid receptor antagonist is generally not recommended. (etiqueta de Candesartán, Interacciones medicamentosas)

  • Espironolactona e hidroclorotiazidaantagonista de la aldosteronaGrave

    Triple combination of candesartan cilexetil with an ACE-inhibitor and a mineralocorticoid receptor antagonist is generally not recommended. (etiqueta de Candesartán, Interacciones medicamentosas)

  • FludrocortisonacorticosteroideGrave

    Triple combination of candesartan cilexetil with an ACE-inhibitor and a mineralocorticoid receptor antagonist is generally not recommended. (etiqueta de Candesartán, Interacciones medicamentosas)

  • Fosinoprilinhibidor de la ECAGrave

    Triple combination of candesartan cilexetil with an ACE-inhibitor and a mineralocorticoid receptor antagonist is generally not recommended. (etiqueta de Candesartán, Interacciones medicamentosas)

  • Fosinopril e hidroclorotiazidainhibidor de la ECAGrave

    Triple combination of candesartan cilexetil with an ACE-inhibitor and a mineralocorticoid receptor antagonist is generally not recommended. (etiqueta de Candesartán, Interacciones medicamentosas)

  • Lisinoprilinhibidor de la ECAGrave

    Triple combination of candesartan cilexetil with an ACE-inhibitor and a mineralocorticoid receptor antagonist is generally not recommended. (etiqueta de Candesartán, Interacciones medicamentosas)

  • Lisinopril e hidroclorotiazidainhibidor de la ECAGrave

    Triple combination of candesartan cilexetil with an ACE-inhibitor and a mineralocorticoid receptor antagonist is generally not recommended. (etiqueta de Candesartán, Interacciones medicamentosas)

  • Metolazonadiurético tiazídicoGrave

    Other Antihypertensive Drugs When metolazone tablets, USP, are used with other antihypertensive drugs, particular care must be taken to avoid excessive reduction of blood pressure, especially during initial therapy. (etiqueta de Metolazona, Advertencias)

  • MinoxidilvasodilatadorGrave

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (etiqueta de Minoxidil, Advertencia en recuadro)

  • Moexiprilinhibidor de la ECAGrave

    Triple combination of candesartan cilexetil with an ACE-inhibitor and a mineralocorticoid receptor antagonist is generally not recommended. (etiqueta de Candesartán, Interacciones medicamentosas)

  • Perindoprilinhibidor de la ECAGrave

    Triple combination of candesartan cilexetil with an ACE-inhibitor and a mineralocorticoid receptor antagonist is generally not recommended. (etiqueta de Candesartán, Interacciones medicamentosas)

  • PotasioVitaminas y mineralesGrave

    Estos medicamentos reducen la excreción de potasio; añadir suplementos de potasio o sustitutos de la sal puede causar hiperpotasemia, que afecta al ritmo cardíaco. (NIH Office of Dietary Supplements, Potassium)

  • Quinaprilinhibidor de la ECAGrave

    Triple combination of candesartan cilexetil with an ACE-inhibitor and a mineralocorticoid receptor antagonist is generally not recommended. (etiqueta de Candesartán, Interacciones medicamentosas)

  • Quinapril e hidroclorotiazidainhibidor de la ECAGrave

    Triple combination of candesartan cilexetil with an ACE-inhibitor and a mineralocorticoid receptor antagonist is generally not recommended. (etiqueta de Candesartán, Interacciones medicamentosas)

  • Ramiprilinhibidor de la ECAGrave

    Triple combination of candesartan cilexetil with an ACE-inhibitor and a mineralocorticoid receptor antagonist is generally not recommended. (etiqueta de Candesartán, Interacciones medicamentosas)

  • Tadalafiloinhibidor de la PDE5Grave

    …coadministration of an alpha-blocker and CIALIS for the treatment of BPH has not been adequately studied, and due to the potential vasodilatory effects of combined use resulting in blood pressure lowering, the combination of CIALIS and alpha-blockers is not recommended for the treatment of BPH. [see Dosage and Administration ( 2.7 ), Drug Interactions ( 7.1 ),… (etiqueta de Tadalafilo, Advertencias y precauciones)

  • Trandolaprilinhibidor de la ECAGrave

    Triple combination of candesartan cilexetil with an ACE-inhibitor and a mineralocorticoid receptor antagonist is generally not recommended. (etiqueta de Candesartán, Interacciones medicamentosas)

Interacciones moderadas (138)

  • Acetazolamidainhibidor de la anhidrasa carbónicaModerada

    Symptomatic hypotension is most likely to occur in patients who have been volume and/or salt depleted as a result of prolonged diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. (etiqueta de Candesartán, Advertencias y precauciones)

  • NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect ( 7 ). (etiqueta de Candesartán, Interacciones medicamentosas)

  • Ácido acetilsalicílico y dipiridamolantiagregante plaquetarioModerada

    NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect ( 7 ). (etiqueta de Candesartán, Interacciones medicamentosas)

  • Ácido etacrínicodiurético de asaModerada

    Symptomatic hypotension is most likely to occur in patients who have been volume and/or salt depleted as a result of prolonged diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. (etiqueta de Candesartán, Advertencias y precauciones)

  • Ácido mefenámicoAINEModerada

    NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect ( 7 ). (etiqueta de Candesartán, Interacciones medicamentosas)

  • AdrenalinasimpaticomiméticoModerada

    Very rarely, hypotension may be severe such that it may warrant the use of intravenous fluids and/or vasopressors. (etiqueta de Candesartán, Advertencias y precauciones)

  • AlfuzosinaalfabloqueanteModerada

    Postural hypotension/syncope: Care should be taken in patients with symptomatic hypotension or who have had a hypotensive response to other medications or are concomitantly treated with antihypertensive medication or nitrates ( 5.1 ) (etiqueta de Alfuzosina, Advertencias y precauciones)

  • Amiloridadiurético ahorrador de potasioModerada

    Symptomatic hypotension is most likely to occur in patients who have been volume and/or salt depleted as a result of prolonged diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. (etiqueta de Candesartán, Advertencias y precauciones)

  • Anfepramonaestimulante del SNCModerada

    Very rarely, hypotension may be severe such that it may warrant the use of intravenous fluids and/or vasopressors. (etiqueta de Candesartán, Advertencias y precauciones)

  • AripiprazolantipsicóticoModerada

    Antihypertensive Drugs Due to its alpha-adrenergic antagonism, aripiprazole has the potential to enhance the effect of certain antihypertensive agents. (etiqueta de Aripiprazol, Interacciones medicamentosas)

  • Armodafiniloestimulante del SNCModerada

    There was also a slightly greater proportion of patients on NUVIGIL requiring new or increased use of antihypertensive medications (2.9%) compared to patients on placebo (1.8%). (etiqueta de Armodafinilo, Advertencias y precauciones)

  • Articaína y adrenalinaanestésico localModerada

    Very rarely, hypotension may be severe such that it may warrant the use of intravenous fluids and/or vasopressors. (etiqueta de Candesartán, Advertencias y precauciones)

  • AsenapinaantipsicóticoModerada

    Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medications, patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure, or conduction abnormalities), and patients… (etiqueta de Asenapina, Advertencias y precauciones)

  • AtenololbetabloqueanteModerada

    Because of its relative beta 1 selectivity, however, TENORMIN may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (etiqueta de Atenolol, Advertencias)

  • Atenolol y clortalidonabetabloqueanteModerada

    Symptomatic hypotension is most likely to occur in patients who have been volume and/or salt depleted as a result of prolonged diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. (etiqueta de Candesartán, Advertencias y precauciones)

  • Atomoxetinainhibidor de la recaptación de noradrenalinaModerada

    Antihypertensive Drugs Prevention or Management Increase the frequency of monitoring blood pressure and adjust atomoxetine oral solution dosage as clinically appropriate. (etiqueta de Atomoxetina, Interacciones medicamentosas)

  • Avanafiloinhibidor de la PDE5Moderada

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (etiqueta de Avanafilo, Advertencias y precauciones)

  • Benzfetaminaestimulante del SNCModerada

    Very rarely, hypotension may be severe such that it may warrant the use of intravenous fluids and/or vasopressors. (etiqueta de Candesartán, Advertencias y precauciones)

  • BisoprololbetabloqueanteModerada

    Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (etiqueta de Bisoprolol, Advertencias)

  • Bisoprolol e hidroclorotiazidabetabloqueanteModerada

    Symptomatic hypotension is most likely to occur in patients who have been volume and/or salt depleted as a result of prolonged diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. (etiqueta de Candesartán, Advertencias y precauciones)

  • BortezomibModerada

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (etiqueta de Bortezomib, Advertencias y precauciones)

  • BrexpiprazolantipsicóticoModerada

    Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (etiqueta de Brexpiprazol, Advertencias y precauciones)

  • Brimonidinaagonista alfa-adrenérgicoModerada

    Antihypertensives/Cardiac Glycosides Because brimonidine tartrate ophthalmic solution 0.1% and 0.15% may reduce blood pressure, caution in using drugs such as antihypertensives and/or cardiac glycosides with brimonidine tartrate ophthalmic solution 0.1% and 0.15% is advised. (etiqueta de Brimonidina, Interacciones medicamentosas)

  • Brimonidina y timololagonista alfa-adrenérgicoModerada

    Antihypertensives/Cardiac Glycosides Because brimonidine tartrate/timolol maleate ophthalmic solution may reduce blood pressure, caution in using drugs such as antihypertensives and/or cardiac glycosides with brimonidine tartrate/timolol maleate ophthalmic solution is advised. (etiqueta de Brimonidina y timolol, Interacciones medicamentosas)

  • Very rarely, hypotension may be severe such that it may warrant the use of intravenous fluids and/or vasopressors. (etiqueta de Candesartán, Advertencias y precauciones)

  • Bromocriptinaagonista de la dopaminaModerada

    Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

  • Bumetanidadiurético de asaModerada

    Symptomatic hypotension is most likely to occur in patients who have been volume and/or salt depleted as a result of prolonged diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. (etiqueta de Candesartán, Advertencias y precauciones)

  • Bupivacaína y adrenalinaanestésico localModerada

    Very rarely, hypotension may be severe such that it may warrant the use of intravenous fluids and/or vasopressors. (etiqueta de Candesartán, Advertencias y precauciones)

  • NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect ( 7 ). (etiqueta de Candesartán, Interacciones medicamentosas)

  • NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect ( 7 ). (etiqueta de Candesartán, Interacciones medicamentosas)

  • Candesartán e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Moderada

    Symptomatic hypotension is most likely to occur in patients who have been volume and/or salt depleted as a result of prolonged diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. (etiqueta de Candesartán, Advertencias y precauciones)

  • CarbidopaModerada

    Symptomatic postural hypotension has occurred when carbidopa, given with levodopa or carbidopa-levodopa combination products, was added to the treatment of a patient receiving antihypertensive drugs. (etiqueta de Carbidopa, Interacciones medicamentosas)

  • Carbidopa y levodopafármaco dopaminérgicoModerada

    Antihypertensive drugs: May cause symptomatic postural hypotension. (etiqueta de Carbidopa y levodopa, Interacciones medicamentosas)

  • Carbidopa, levodopa y entacaponafármaco dopaminérgicoModerada

    Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (etiqueta de Carbidopa, levodopa y entacapona, Interacciones medicamentosas)

  • CariprazinaantipsicóticoModerada

    Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive medications), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (etiqueta de Cariprazina, Advertencias y precauciones)

  • CarvedilolbetabloqueanteModerada

    COREG may be used with caution, however, in patients who do not respond to, or cannot tolerate, other antihypertensive agents. (etiqueta de Carvedilol, Advertencias y precauciones)

  • CelecoxibAINEModerada

    NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect ( 7 ). (etiqueta de Candesartán, Interacciones medicamentosas)

  • Ciclobenzaprinarelajante muscularModerada

    …concomitant use of TONMYA with: MAO inhibitors may be life-threatening [see Contraindications (4) ] , Alcohol, barbiturates, and other CNS depressants may increase the risk of adverse reactions associated with these drugs, Tramadol may increase the seizure risk, Guanethidine or other similar acting drugs may block the antihypertensive action of these drugs. (etiqueta de Ciclobenzaprina, Interacciones medicamentosas)

  • CiclosporinainmunosupresorModerada

    Caution is also required when cyclosporine is coadministered with potassium sparing drugs (e.g., angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists), potassium-containing drugs as well as in patients on a potassium rich diet. (etiqueta de Ciclosporina, Interacciones medicamentosas)

  • Citrato de potasiosuplemento de potasioModerada

    Agents Increasing Serum Potassium Co-administration of candesartan cilexetil with potassium sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia. (etiqueta de Candesartán, Interacciones medicamentosas)

  • Clorotiazidadiurético tiazídicoModerada

    Symptomatic hypotension is most likely to occur in patients who have been volume and/or salt depleted as a result of prolonged diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. (etiqueta de Candesartán, Advertencias y precauciones)

  • Clortalidonadiurético tiazídicoModerada

    Symptomatic hypotension is most likely to occur in patients who have been volume and/or salt depleted as a result of prolonged diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. (etiqueta de Candesartán, Advertencias y precauciones)

  • Cloruro de potasiosuplemento de potasioModerada

    Agents Increasing Serum Potassium Co-administration of candesartan cilexetil with potassium sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia. (etiqueta de Candesartán, Interacciones medicamentosas)

  • Dexmetilfenidatoestimulante del SNCModerada

    • Antihypertensive Drugs: Monitor blood pressure. (etiqueta de Dexmetilfenidato, Interacciones medicamentosas)

  • DiclofenacoAINEModerada

    NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect ( 7 ). (etiqueta de Candesartán, Interacciones medicamentosas)

  • NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect ( 7 ). (etiqueta de Candesartán, Interacciones medicamentosas)

  • DiflunisalAINEModerada

    NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect ( 7 ). (etiqueta de Candesartán, Interacciones medicamentosas)

  • DobutaminasimpaticomiméticoModerada

    Very rarely, hypotension may be severe such that it may warrant the use of intravenous fluids and/or vasopressors. (etiqueta de Candesartán, Advertencias y precauciones)

  • Drospirenona y etinilestradiolanticonceptivo oralModerada

    Medications that may increase serum potassium concentration include ACE inhibitors, angiotensin-II receptor antagonists, potassium-sparing diuretics, potassium supplementation, heparin, aldosterone antagonists, and NSAIDS. (etiqueta de Drospirenona y etinilestradiol, Advertencias y precauciones)

  • DroxidopasimpaticomiméticoModerada

    Very rarely, hypotension may be severe such that it may warrant the use of intravenous fluids and/or vasopressors. (etiqueta de Candesartán, Advertencias y precauciones)

  • DuloxetinaIRSNModerada

    The risk of BP decreases may be greater in patients taking concomitant medications that induce orthostatic hypotension (such as antihypertensives) or are potent CYP1A2 inhibitors [see Drug Interactions ( 7.1 )] and in patients taking duloxetine delayed-release capsules at doses above 60 mg daily. (etiqueta de Duloxetina, Advertencias y precauciones)

  • EfedrinasimpaticomiméticoModerada

    Very rarely, hypotension may be severe such that it may warrant the use of intravenous fluids and/or vasopressors. (etiqueta de Candesartán, Advertencias y precauciones)

  • Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)

  • Epoprostenolanálogo de prostaglandinaModerada

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etiqueta de Epoprostenol, Interacciones medicamentosas)

  • EsmololbetabloqueanteModerada

    Antihypertensive agents clonidine, guanfacine, or moxonidine: Beta blockers also increase the risk of clonidine-, guanfacine-, or moxonidine-withdrawal rebound hypertension. (etiqueta de Esmolol, Interacciones medicamentosas)

  • EtodolacoAINEModerada

    NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect ( 7 ). (etiqueta de Candesartán, Interacciones medicamentosas)

  • Fampridinasuplemento de potasioModerada

    Agents Increasing Serum Potassium Co-administration of candesartan cilexetil with potassium sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia. (etiqueta de Candesartán, Interacciones medicamentosas)

  • Fendimetrazinaestimulante del SNCModerada

    Very rarely, hypotension may be severe such that it may warrant the use of intravenous fluids and/or vasopressors. (etiqueta de Candesartán, Advertencias y precauciones)

  • Fenelzinainhibidor de la MAOModerada

    …hydrochloride desipramine hydrochloride imipramine hydrochloride doxepin carbamazepine cyclobenzaprine HCl amoxapine maprotiline HCl trimipramine maleate protriptyline HCl mirtazapine Phenelzine sulfate should be used with caution in combination with antihypertensive drugs, including thiazide diuretics and β-blockers, since exaggerated hypotensive effects may result. (etiqueta de Fenelzina, Advertencias)

  • FenilefrinadescongestionanteModerada

    Very rarely, hypotension may be severe such that it may warrant the use of intravenous fluids and/or vasopressors. (etiqueta de Candesartán, Advertencias y precauciones)

  • FenoprofenoAINEModerada

    NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect ( 7 ). (etiqueta de Candesartán, Interacciones medicamentosas)

  • Fenterminaestimulante del SNCModerada

    Very rarely, hypotension may be severe such that it may warrant the use of intravenous fluids and/or vasopressors. (etiqueta de Candesartán, Advertencias y precauciones)

  • FlurbiprofenoAINEModerada

    NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect ( 7 ). (etiqueta de Candesartán, Interacciones medicamentosas)

  • Furosemidadiurético de asaModerada

    Symptomatic hypotension is most likely to occur in patients who have been volume and/or salt depleted as a result of prolonged diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. (etiqueta de Candesartán, Advertencias y precauciones)

  • Hidroclorotiazidadiurético tiazídicoModerada

    Symptomatic hypotension is most likely to occur in patients who have been volume and/or salt depleted as a result of prolonged diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. (etiqueta de Candesartán, Advertencias y precauciones)

  • NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect ( 7 ). (etiqueta de Candesartán, Interacciones medicamentosas)

  • IbuprofenoAINEModerada

    NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect ( 7 ). (etiqueta de Candesartán, Interacciones medicamentosas)

  • NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect ( 7 ). (etiqueta de Candesartán, Interacciones medicamentosas)

  • IloperidonaantipsicóticoModerada

    Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive medications), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (etiqueta de Iloperidona, Advertencias y precauciones)

  • Indapamidadiurético tiazídicoModerada

    Symptomatic hypotension is most likely to occur in patients who have been volume and/or salt depleted as a result of prolonged diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. (etiqueta de Candesartán, Advertencias y precauciones)

  • IndometacinaAINEModerada

    NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect ( 7 ). (etiqueta de Candesartán, Interacciones medicamentosas)

  • Irbesartán e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Moderada

    Symptomatic hypotension is most likely to occur in patients who have been volume and/or salt depleted as a result of prolonged diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. (etiqueta de Candesartán, Advertencias y precauciones)

  • Isoprenalina (isoproterenol)agonista beta-adrenérgicoModerada

    Very rarely, hypotension may be severe such that it may warrant the use of intravenous fluids and/or vasopressors. (etiqueta de Candesartán, Advertencias y precauciones)

  • KetoprofenoAINEModerada

    NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect ( 7 ). (etiqueta de Candesartán, Interacciones medicamentosas)

  • KetorolacoAINEModerada

    NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect ( 7 ). (etiqueta de Candesartán, Interacciones medicamentosas)

  • Lidocaína y adrenalinaanestésico localModerada

    Very rarely, hypotension may be severe such that it may warrant the use of intravenous fluids and/or vasopressors. (etiqueta de Candesartán, Advertencias y precauciones)

  • Litiofármaco serotoninérgicoModerada

    Lithium: Increases in serum lithium concentrations and toxicity ( 7 ). (etiqueta de Candesartán, Interacciones medicamentosas)

  • Losartán e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Moderada

    Symptomatic hypotension is most likely to occur in patients who have been volume and/or salt depleted as a result of prolonged diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. (etiqueta de Candesartán, Advertencias y precauciones)

  • LumateperonaantipsicóticoModerada

    Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (etiqueta de Lumateperona, Advertencias y precauciones)

  • LurasidonaantipsicóticoModerada

    Patients at increased risk of these adverse reactions or at increased risk of developing complications from hypotension include those with dehydration, hypovolemia, treatment with antihypertensive medication, history of cardiovascular disease (e.g., heart failure, myocardial infarction, ischemia, or conduction abnormalities), history of cerebrovascular disease,… (etiqueta de Lurasidona, Advertencias y precauciones)

  • MecamilaminaantihipertensivoModerada

    The action of Mecamylamine HCl may be potentiated by anesthesia, other antihypertensive drugs and alcohol. (etiqueta de Mecamilamina, Interacciones medicamentosas)

  • MeloxicamAINEModerada

    NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect ( 7 ). (etiqueta de Candesartán, Interacciones medicamentosas)

  • Metanfetaminaestimulante del SNCModerada

    Very rarely, hypotension may be severe such that it may warrant the use of intravenous fluids and/or vasopressors. (etiqueta de Candesartán, Advertencias y precauciones)

  • Metilfenidatoestimulante del SNCModerada

    Antihypertensive Drugs: Monitor blood pressure. (etiqueta de Metilfenidato, Interacciones medicamentosas)

  • Metoprolol e hidroclorotiazidabetabloqueanteModerada

    Symptomatic hypotension is most likely to occur in patients who have been volume and/or salt depleted as a result of prolonged diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. (etiqueta de Candesartán, Advertencias y precauciones)

  • Midodrinaagonista alfa-adrenérgicoModerada

    Very rarely, hypotension may be severe such that it may warrant the use of intravenous fluids and/or vasopressors. (etiqueta de Candesartán, Advertencias y precauciones)

  • Mirabegrónagonista beta-adrenérgicoModerada

    Very rarely, hypotension may be severe such that it may warrant the use of intravenous fluids and/or vasopressors. (etiqueta de Candesartán, Advertencias y precauciones)

  • MirtazapinaantidepresivoModerada

    REMERON/REMERONSolTab should be used with caution in patients with known cardiovascular or cerebrovascular disease that could be exacerbated by hypotension (history of myocardial infarction, angina, or ischemic stroke) and conditions that would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medication). (etiqueta de Mirtazapina, Advertencias y precauciones)

  • Modafiniloestimulante del SNCModerada

    Very rarely, hypotension may be severe such that it may warrant the use of intravenous fluids and/or vasopressors. (etiqueta de Candesartán, Advertencias y precauciones)

  • NabumetonaAINEModerada

    NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect ( 7 ). (etiqueta de Candesartán, Interacciones medicamentosas)

  • NaproxenoAINEModerada

    NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect ( 7 ). (etiqueta de Candesartán, Interacciones medicamentosas)

  • NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect ( 7 ). (etiqueta de Candesartán, Interacciones medicamentosas)

  • NateglinidameglitinidaModerada

    Agents Increasing Serum Potassium Co-administration of candesartan cilexetil with potassium sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia. (etiqueta de Candesartán, Interacciones medicamentosas)

  • NiacinaModerada

    Antihypertensive Therapy Niacin may potentiate the effects of ganglionic blocking agents and vasoactive drugs resulting in postural hypotension. (etiqueta de Niacina, Interacciones medicamentosas)

  • Nimodipinobloqueador de los canales de calcio dihidropiridínicoModerada

    Blood Pressure Lowering Drugs Nimodipine may increase the blood pressure lowering effect of concomitantly administered anti-hypertensives such as diuretics, beta-blockers, ACE inhibitors, angiotensin receptor blockers, other calcium channel blockers, α-adrenergic blockers, PDE5 inhibitors, and α-methyldopa. (etiqueta de Nimodipino, Interacciones medicamentosas)

  • NitroglicerinanitratoModerada

    Antihypertensives: Possible additive hypotensive effects. (etiqueta de Nitroglicerina, Interacciones medicamentosas)

  • OlanzapinaantipsicóticoModerada

    …of myocardial infarction or ischemia, heart failure, or conduction abnormalities), cerebrovascular disease, and conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications) where the occurrence of syncope, or hypotension and/or bradycardia might put the patient at increased medical risk. (etiqueta de Olanzapina, Advertencias y precauciones)

  • Olanzapina y fluoxetinaantipsicóticoModerada

    …and fluoxetine capsules should be used with particular caution in patients with known cardiovascular disease (history of myocardial infarction or ischemia, heart failure, or conduction abnormalities), cerebrovascular disease, or conditions that would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications). (etiqueta de Olanzapina y fluoxetina, Advertencias y precauciones)

  • Olmesartán e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Moderada

    Symptomatic hypotension is most likely to occur in patients who have been volume and/or salt depleted as a result of prolonged diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. (etiqueta de Candesartán, Advertencias y precauciones)

  • Olmesartán, amlodipino e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Moderada

    Symptomatic hypotension is most likely to occur in patients who have been volume and/or salt depleted as a result of prolonged diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. (etiqueta de Candesartán, Advertencias y precauciones)

  • NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect ( 7 ). (etiqueta de Candesartán, Interacciones medicamentosas)

  • OxaprozinaAINEModerada

    NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect ( 7 ). (etiqueta de Candesartán, Interacciones medicamentosas)

  • OximetazolinadescongestionanteModerada

    Very rarely, hypotension may be severe such that it may warrant the use of intravenous fluids and/or vasopressors. (etiqueta de Candesartán, Advertencias y precauciones)

  • PaliperidonaantipsicóticoModerada

    Use ERZOFRI with caution in patients with known cardiovascular disease (e.g., heart failure, history of myocardial infarction or ischemia, conduction abnormalities), cerebrovascular disease, or conditions that predispose the patient to hypotension (e.g., dehydration, hypovolemia, and treatment with antihypertensive medications). (etiqueta de Paliperidona, Advertencias y precauciones)

  • NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect ( 7 ). (etiqueta de Candesartán, Interacciones medicamentosas)

  • PazopanibModerada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • PentoxifilinametilxantinaModerada

    Small decreases in blood pressure have been observed in some patients treated with pentoxifylline extended-release tablets; periodic systemic blood pressure monitoring is recommended for patients receiving concomitant antihypertensive therapy. (etiqueta de Pentoxifilina, Interacciones medicamentosas)

  • PiroxicamAINEModerada

    NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect ( 7 ). (etiqueta de Candesartán, Interacciones medicamentosas)

  • Poliestirenosulfonato de sodiosuplemento de potasioModerada

    Agents Increasing Serum Potassium Co-administration of candesartan cilexetil with potassium sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia. (etiqueta de Candesartán, Interacciones medicamentosas)

  • PrazosinaalfabloqueanteModerada

    Syncopal episodes have usually occurred within 30 to 90 minutes of the initial dose of the drug; occasionally, they have been reported in association with rapid dosage increases or the introduction of another antihypertensive drug into the regimen of a patient taking high doses of prazosin hydrochloride capsules. (etiqueta de Prazosina, Advertencias)

  • Prilocaína y adrenalinaanestésico localModerada

    Very rarely, hypotension may be severe such that it may warrant the use of intravenous fluids and/or vasopressors. (etiqueta de Candesartán, Advertencias y precauciones)

  • PseudoefedrinadescongestionanteModerada

    Very rarely, hypotension may be severe such that it may warrant the use of intravenous fluids and/or vasopressors. (etiqueta de Candesartán, Advertencias y precauciones)

  • QuetiapinaantipsicóticoModerada

    Quetiapine should be used with particular caution in patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure, or conduction abnormalities), cerebrovascular disease, or conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications). (etiqueta de Quetiapina, Advertencias y precauciones)

  • RepaglinidameglitinidaModerada

    Agents Increasing Serum Potassium Co-administration of candesartan cilexetil with potassium sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia. (etiqueta de Candesartán, Interacciones medicamentosas)

  • RiociguatvasodilatadorModerada

    Consider the potential for symptomatic hypotension or ischemia in patients with hypovolemia, severe left ventricular outflow obstruction, resting hypotension, autonomic dysfunction, or concomitant treatment with antihypertensives or strong CYP and P-gp/BCRP inhibitors [see Drug Interactions (7.2) and Clinical Pharmacology (12.3) ] . (etiqueta de Riociguat, Advertencias y precauciones)

  • RisperidonaantipsicóticoModerada

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (etiqueta de Risperidona, Advertencias y precauciones)

  • SalsalatoAINEModerada

    NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect ( 7 ). (etiqueta de Candesartán, Interacciones medicamentosas)

  • Sildenafiloinhibidor de la PDE5Moderada

    Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (etiqueta de Sildenafilo, Advertencias y precauciones)

  • SilodosinaalfabloqueanteModerada

    However, patients in the Phase 3 clinical studies taking concomitant antihypertensive medications with silodosin capsules did not experience a significant increase in the incidence of syncope, dizziness, or orthostasis. (etiqueta de Silodosina, Advertencias y precauciones)

  • SorafenibModerada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • SulindacoAINEModerada

    NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect ( 7 ). (etiqueta de Candesartán, Interacciones medicamentosas)

  • Sumatriptán y naproxenotriptánModerada

    NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect ( 7 ). (etiqueta de Candesartán, Interacciones medicamentosas)

  • SunitinibModerada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • TacrolimusinmunosupresorModerada

    • Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (etiqueta de Tacrolimus, Advertencias y precauciones)

  • Telmisartán e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Moderada

    Symptomatic hypotension is most likely to occur in patients who have been volume and/or salt depleted as a result of prolonged diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. (etiqueta de Candesartán, Advertencias y precauciones)

  • TerazosinaalfabloqueanteModerada

    Risk of Hypotension with Concomitant Use of Other Antihypertensive Agents and Phospodiesterase Type 5 Inhibitors (PDE5-I): Concomitant administration of TEZRULY with antihypertensives or phosphodiesterase-5 (PDE-5) inhibitors can result in additive blood pressure lowering effects and symptomatic hypotension (5.3). (etiqueta de Terazosina, Advertencias y precauciones)

  • TestosteronaandrógenoModerada

    In patients with hypertension on antihypertensive therapy, TLANDO increased the mean systolic/diastolic BP by 4.8/1.6 mm Hg from baseline. [see Adverse Reactions ( 6.1 )] . (etiqueta de Testosterona, Advertencias y precauciones)

  • TolmetinaAINEModerada

    NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect ( 7 ). (etiqueta de Candesartán, Interacciones medicamentosas)

  • TolvaptánModerada

    Monitor serum potassium during concomitant therapy with ( 7.2 ): Angiotensin receptor blockers Angiotensin converting enzyme inhibitors Potassium sparing diuretics 7.1 CYP3A Inhibitors and Inducers Strong CYP3A Inhibitors Tolvaptan's AUC was 5.4 times as large and C max was 3.5 times as large after co-administration of tolvaptan and 200 mg ketoconazole [see Warnings… (etiqueta de Tolvaptán, Interacciones medicamentosas)

  • Torasemidadiurético de asaModerada

    Symptomatic hypotension is most likely to occur in patients who have been volume and/or salt depleted as a result of prolonged diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. (etiqueta de Candesartán, Advertencias y precauciones)

  • TrazodonaantidepresivoModerada

    Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (etiqueta de Trazodona, Advertencias y precauciones)

  • Triamterenodiurético ahorrador de potasioModerada

    Symptomatic hypotension is most likely to occur in patients who have been volume and/or salt depleted as a result of prolonged diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. (etiqueta de Candesartán, Advertencias y precauciones)

  • Triamtereno e hidroclorotiazidadiurético ahorrador de potasioModerada

    Symptomatic hypotension is most likely to occur in patients who have been volume and/or salt depleted as a result of prolonged diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. (etiqueta de Candesartán, Advertencias y precauciones)

  • Valsartán e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Moderada

    Symptomatic hypotension is most likely to occur in patients who have been volume and/or salt depleted as a result of prolonged diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. (etiqueta de Candesartán, Advertencias y precauciones)

  • Vardenafiloinhibidor de la PDE5Moderada

    Vardenafil hydrochloride tablets can potentiate the hypotensive effects of nitrates, alpha- blockers, and antihypertensives. (etiqueta de Vardenafilo, Interacciones medicamentosas)

  • VenlafaxinaIRSNModerada

    Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (etiqueta de Venlafaxina, Interacciones medicamentosas)

  • Vibegrónagonista beta-adrenérgicoModerada

    Very rarely, hypotension may be severe such that it may warrant the use of intravenous fluids and/or vasopressors. (etiqueta de Candesartán, Advertencias y precauciones)

  • ZiprasidonaantipsicóticoModerada

    Ziprasidone should be used with particular caution in patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure or conduction abnormalities), cerebrovascular disease, or conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications). (etiqueta de Ziprasidona, Advertencias y precauciones)

Menciones leves (18)

  • ButorfanolopioideLeve

    In such cases, butorphanol should be discontinued and the hypertension treated with antihypertensive drugs. (etiqueta de Butorfanol, Advertencias)

  • ClorpromazinaantipsicóticoLeve

    Chlorpromazine may counteract the antihypertensive effect of guanethidine and related compounds. (etiqueta de Clorpromazina, Advertencias)

  • Desipraminaantidepresivo tricíclicoLeve

    This drug is capable of blocking the antihypertensive effect of guanethidine and similarly acting compounds. (etiqueta de Desipramina, Advertencias)

  • Desogestrel y etinilestradiolanticonceptivo oralLeve

    If other contraceptive methods are not suitable, hormonal contraceptive therapy may continue combined with antihypertensive therapy. (etiqueta de Desogestrel y etinilestradiol, Advertencias)

  • Dexanfetaminaestimulante del SNCLeve

    Antihypertensives Amphetamines may antagonize the hypotensive effects of antihypertensives. (etiqueta de Dexanfetamina, Interacciones medicamentosas)

  • HidralazinavasodilatadorLeve

    When other potent parenteral antihypertensive drugs, such as diazoxide, are used in combination with hydralazine, patients should be continuously observed for several hours for any excessive fall in blood pressure. (etiqueta de Hidralazina, Interacciones medicamentosas)

  • ACE Inhibitors FIRAZYR is a bradykinin B2 receptor antagonist and thereby has the potential to have a pharmacodynamic interaction with ACE inhibitors where FIRAZYR may attenuate the antihypertensive effect of ACE inhibitors. (etiqueta de Icatibant, Interacciones medicamentosas)

  • Isradipinobloqueador de los canales de calcio dihidropiridínicoLeve

    In a study in hypertensive patients, addition of isradipine to existing hydrochlorothiazide therapy did not result in any unexpected adverse effects, and isradipine had an additional antihypertensive effect. (etiqueta de Isradipino, Interacciones medicamentosas)

  • MetildopaantihipertensivoLeve

    Drug Interactions When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. (etiqueta de Metildopa, Interacciones medicamentosas)

  • MetoprololbetabloqueanteLeve

    Because of its relative beta 1 cardio-selectivity, however, Metoprolol Tartrate Tablets may be used in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (etiqueta de Metoprolol, Advertencias y precauciones)

  • MexiletinaantiarrítmicoLeve

    In a large compassionate use program mexiletine has been used concurrently with commonly employed antianginal, antihypertensive, and anticoagulant drugs without observed interactions. (etiqueta de Mexiletina, Interacciones medicamentosas)

  • Nifedipinobloqueador de los canales de calcio dihidropiridínicoLeve

    Candesartan: No significant drug interaction has been reported in studies with candesartan cilexitil given together with nifedipine. (etiqueta de Nifedipino, Interacciones medicamentosas)

  • Nisoldipinobloqueador de los canales de calcio dihidropiridínicoLeve

    The blood pressure effect of SULAR tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy. (etiqueta de Nisoldipino, Interacciones medicamentosas)

  • NitroprusiatovasodilatadorLeve

    Hypertensive patients, and patients concomitantly receiving other antihypertensive medications, may be more sensitive to the effects of sodium nitroprusside than normal subjects. (etiqueta de Nitroprusiato, Advertencias)

  • Nortriptilinaantidepresivo tricíclicoLeve

    The antihypertensive action of guanethidine and similar agents may be blocked. (etiqueta de Nortriptilina, Advertencias)

  • ProclorperazinaantipsicóticoLeve

    Antihypertensive effects of guanethidine and related compounds may be counteracted when phenothiazines are used concomitantly. (etiqueta de Proclorperazina, Precauciones)

  • Protriptilinaantidepresivo tricíclicoLeve

    Protriptyline may block the antihypertensive effect of guanethidine or similarly acting compounds. (etiqueta de Protriptilina, Advertencias)

  • TrifluoperazinaantipsicóticoLeve

    Antihypertensive effects of guanethidine and related compounds may be counteracted when phenothiazines are used concurrently. (etiqueta de Trifluoperazina, Precauciones)

Compruebe Candesartán frente a todo lo que toma. Añada su lista completa; todos los pares se comprueban a la vez.

Abrir en el verificador

No es un consejo médico. La gravedad refleja la redacción de la etiqueta, no sus circunstancias. Una señal «grave» puede ser algo habitual bajo supervisión y una «leve» puede ser importante a dosis altas. Consulte a un farmacéutico.